Hyperhomocysteinaemia in Behcet's disease
Küçük Resim Yok
Tarih
2001
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Oxford Univ Press
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective. Arterial and venous thrombosis are among the clinical features of Behcet's disease (BD), the pathogenesis of which is not completely understood. In this study, we investigated whether hyperhomocysteinaemia, being a well known risk factor for thrombosis, is also a contributive risk factor for the arterial and venous thrombosis of ED. Method's. Eighty-four patients fulfilling the criteria of the International Study Group for Behcet's Disease (54 males, 30 females, mean age 36 +/- 9 yr) were enrolled. All the patients were carefully screened for a history of venous thrombosis and were separated into two groups with respect to thrombosis history. Thirty-six healthy individuals (23 males, 13 females), matched for age and sex with the ED group, were included as a negative control group. Patients were excluded if they had any condition that might affect plasma homocysteine concentration. As methotrexate (MTX) causes hyperhomocysteinaemia, we also included 29 rheumatoid arthritis patients (five males, 24 females) receiving MTX weekly. Fasting plasma homocysteine concentrations were measured by high-performance liquid chromatography. The data were analysed with the chi (2) test and Student's T-test. Results. The highest homocysteine concentrations were found in the MTX group (17.5 +/- 5.3 mu mol/l). Mean plasma homocysteine concentrations in ED patients were significantly higher than in the healthy controls (11.5 +/- 5.3 vs 8.8 +/- 3.1 mu mol/l, P < 0.001). Among ED patients with a history of thrombosis, 20 of 31 (64%) had hyperhomocysteinaemia, and this was significantly higher than in those without thrombosis (9%). On the other hand, there was no significant difference between patients with non-thrombotic ED and healthy controls (P > 0.05). In patients with thrombosis, we found no correlation between the duration of the postthrombotic period and homocysteine concentration. Among all the variables investigated, only hyperhomocysteinaemia was found to be related to thrombosis. Conclusion. Hyperhomocysteinaemia may be assumed to be an independent risk factor for venous thrombosis in ED. Unlike the factor V Leiden mutation, hyperhomocysteinaemia is a correctable risk factor. This finding might lead to new avenues in the prophylaxis of thrombosis in ED.
Açıklama
Anahtar Kelimeler
Behcet's disease, homocysteine, hyperhomocysteinaemia
Kaynak
Rheumatology
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
40
Sayı
6
